Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1997 1
1998 2
1999 1
2000 8
2001 15
2002 51
2003 83
2004 111
2005 126
2006 128
2007 145
2008 253
2009 179
2010 258
2011 215
2012 213
2013 192
2014 232
2015 311
2016 312
2017 304
2018 290
2019 302
2020 334
2021 326
2022 345
2023 331
2024 342
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,844 results

Results by year

Filters applied: . Clear all
Page 1
Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia.
Lamb YN. Lamb YN. Am J Cardiovasc Drugs. 2020 Aug;20(4):381-392. doi: 10.1007/s40256-020-00421-1. Am J Cardiovasc Drugs. 2020. PMID: 32648167 Review.
Rosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA reductase inhibitor (i.e. statin) with particularly strong inhibitory effects on hepatic cholesterol synthesis, and ezetimibe, which inhibits the intestinal absorption of cholesterol …
Rosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA reductase inhibitor (i.e. statin) with particular …
Fixed Combination for the Treatment of Dyslipidaemia.
Ferri N, Ruscica M, Santos RD, Corsini A. Ferri N, et al. Curr Atheroscler Rep. 2023 Oct;25(10):691-699. doi: 10.1007/s11883-023-01142-x. Epub 2023 Sep 16. Curr Atheroscler Rep. 2023. PMID: 37715044 Free PMC article. Review.
Thus, fixed-dose combinations of statins/ezetimibe, bempedoic acid/ezetimibe and statins/fibrates may represent a further armamentarium in the field of lipid-lowering approaches in these individuals. RECENT FINDINGS: The combination therapy of moderate-intensity sta …
Thus, fixed-dose combinations of statins/ezetimibe, bempedoic acid/ezetimibe and statins/fibrates may represent a further arma …
Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights.
Chilbert MR, VanDuyn D, Salah S, Clark CM, Ma Q. Chilbert MR, et al. Drug Des Devel Ther. 2022 Jul 7;16:2177-2186. doi: 10.2147/DDDT.S332352. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35832642 Free PMC article. Review.
The recent approval of a combination tablet of high-intensity rosuvastatin and ezetimibe has introduced a potentially more beneficial option for cholesterol management in addition to the only available combination of moderate intensity simvastatin and ezetimibe. We …
The recent approval of a combination tablet of high-intensity rosuvastatin and ezetimibe has introduced a potentially more beneficial …
PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.
Gunta SP, O'Keefe JH, O'Keefe EL, Lavie CJ. Gunta SP, et al. Prog Cardiovasc Dis. 2023 Jul-Aug;79:12-18. doi: 10.1016/j.pcad.2023.02.007. Epub 2023 Mar 5. Prog Cardiovasc Dis. 2023. PMID: 36871887 Review.
Statins still dominate this landscape, but other agents, often used in combination, potently reduce LDL-C levels, regress atherosclerosis and lower risk of major adverse cardiovascular events (MACE). Ezetimibe lowers LDL-C by reducing intestinal absorption of cholesterol. …
Statins still dominate this landscape, but other agents, often used in combination, potently reduce LDL-C levels, regress atherosclerosis an …
Lipid Lowering Therapy: An Era Beyond Statins.
Abdul-Rahman T, Bukhari SMA, Herrera EC, Awuah WA, Lawrence J, de Andrade H, Patel N, Shah R, Shaikh R, Capriles CAA, Ulusan S, Ahmad S, Corriero AC, Mares AC, Goel A, Hajra A, Bandyopadhyay D, Gupta R. Abdul-Rahman T, et al. Curr Probl Cardiol. 2022 Dec;47(12):101342. doi: 10.1016/j.cpcardiol.2022.101342. Epub 2022 Jul 31. Curr Probl Cardiol. 2022. PMID: 35918009 Review.
These drugs include Bile acids sequestrants, Fibrates, Nicotinic acid, Ezetimibe, Bempedoic acid, Volanesoren, Evinacumab, and the PCSK 9 Inhibitors Evolocumab and Alirocumab. ...
These drugs include Bile acids sequestrants, Fibrates, Nicotinic acid, Ezetimibe, Bempedoic acid, Volanesoren, Evinacumab, and the PC …
Ezetimibe: Likely to Be Beneficial For All.
Herrington WG, Preiss D, Armitage J. Herrington WG, et al. Circulation. 2018 Apr 10;137(15):1583-1584. doi: 10.1161/CIRCULATIONAHA.117.032819. Circulation. 2018. PMID: 29632152 No abstract available.
Dyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?
Lewek J, Banach M. Lewek J, et al. Curr Atheroscler Rep. 2022 Jul;24(7):547-556. doi: 10.1007/s11883-022-01030-w. Epub 2022 Apr 30. Curr Atheroscler Rep. 2022. PMID: 35499807 Review.
RECENT FINDINGS: Among many available groups of lipid-lowering drugs, only bile acid sequestrants are approved for the treatment of dyslipidemia during pregnancy. Ezetimibe and fenofibrate might be considered if benefits outweigh the potential risk. Statins are still contr …
RECENT FINDINGS: Among many available groups of lipid-lowering drugs, only bile acid sequestrants are approved for the treatment of dyslipid …
Therapy for Hyperlipidemia.
Wright J, Subramanian S. Wright J, et al. Med Clin North Am. 2024 Sep;108(5):881-894. doi: 10.1016/j.mcna.2024.03.005. Epub 2024 Jun 4. Med Clin North Am. 2024. PMID: 39084839 Review.
Statins remain first-line agents for ASCVD risk reduction but in high-risk patients, ezetimibe, proprotein convertase subtilisin kexin-9 inhibitors, and bempedoic acid can be added to further reduce individual cardiovascular risk based on results of cardiovascular outcomes …
Statins remain first-line agents for ASCVD risk reduction but in high-risk patients, ezetimibe, proprotein convertase subtilisin kexi …
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.
Tummala R, Gupta M, Devanabanda AR, Bandyopadhyay D, Aronow WS, Ray KK, Mamas M, Ghosh RK. Tummala R, et al. Ann Med. 2022 Dec;54(1):1287-1296. doi: 10.1080/07853890.2022.2059559. Ann Med. 2022. PMID: 35533049 Free PMC article. Review.
The fixed drug combination of bempedoic acid and ezetimibe in a recent phase III showed significant reduction in LDL compared with placebo, which might be a promising future for LDL reduction among statin intolerant patients. ...Given these results, bempedoic acid alone an …
The fixed drug combination of bempedoic acid and ezetimibe in a recent phase III showed significant reduction in LDL compared with pl …
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis.
Lee C, Kwak SH, Han J, Shin JH, Yoo B, Lee YS, Park JS, Lim BJ, Lee JG, Kim YS, Kim SY, Bae SH. Lee C, et al. Eur Respir J. 2024 May 16;63(5):2300580. doi: 10.1183/13993003.00580-2023. Print 2024 May. Eur Respir J. 2024. PMID: 38359963 Free PMC article.
This study aimed to determine whether ezetimibe has therapeutic potential against idiopathic pulmonary fibrosis. METHODS: Primary lung fibroblasts isolated from both humans and mice were employed for mechanistic in vitro experiments. mRNA sequencing of human lung fibroblas …
This study aimed to determine whether ezetimibe has therapeutic potential against idiopathic pulmonary fibrosis. METHODS: Primary lun …
4,844 results